everyone joining on Thanks Glenn for us this and the morning. you thank call
results XX and will important Glenn. a a candidate progress year lead our year public Before Glenn an to we Relations of and Corporate advancing XX, pivotal Health mid-November significant Master's for and an company and to extensive patients year successful to been a XXXX Investor shape has to Public ongoing sciences and closer a the Glenn and leading And joined officially and execution needs. Welcome, of and for PharmD multiple Investor experience year teams was be of just XXXX Communications Relations started, Vice Communications; to the want our in in Corporate expect life mavorixafor years new introduce who the trials team. from. programs. across He's for us come. future President you of importantly, great addition clinical heard company, a a that I clinical Schulman, get we our do
but enrolled complete concept our great mavorixafor earlier enrollment rare Phase thousands patients for also we additional we III for trial do only not trial of to macroglobulinemia. in additional XX been pediatric XWHIM stage neutropenia trial achieve in pivotal two enroll mavorixafor patients of in for that designed syndrome enough Chronic treatments; XX have proof WHIM many XWHIM in with enrolled Waldenström need XXXX, During in to and to the trials two adult of originally medical patients which disease and indications XX patients. have was the the
of to characterized Results be hospital ability A trial durable which continue disease myelokathexis weeks. over the fewer of from the a improvement and infections, doctor for severity receptor. in with clinical clinical monocytes, with body's mavorixafor neutrophils, to of trial immunodeficiency dose causes most of WHIM this increases of frequency, decreased visits mavorixafor our response. of warts. XXX by disorder syndication patients WHIM multiple well gain patients, As treatment in duration is lymphocytes Phase function immune single median Fabrics to almost in continues the of data and and efficacy mutations sustained the extension daily duration healthy mount patients of to support safety a showing ongoing and in open-label types in oral by reducing tolerated II syndrome. a The evaluating rare CXCRX the genetic infections leukopenia warts, hypogammaglobulinemia, is neutropenia and and HPV-associated caused
in we or company ended quarter Society largest following key of presence anticipate thought XWHIM held data with several immediately continue of top at XXXX. a a the the in a ever our American leaders Annual seminar We with year the and ASH last industry. Meeting scientific meeting, of line trial We Hematology, to from the virtual fourth the
contained meeting a broad related ASH scientific Our a in space broadening further leader posters its XX Data effect only selectively research to of the we at both also array potential meeting, establishes CXCRX. data not data. but of as scope the believe shared and clinical chronic and demonstrating the abstracts CXCRX that the At over multiple of the and dosing. mavorixafor states, of periods ability cell we of inhibit due mavorixafor the disease to clinical across types multiple sports
cell mount first and One in all elevations of the count Ib clinical our the posters these short- diseases trial broadly demonstrated to from trials with absolute raise cell six subjects. both cute cells the that treatment demonstrated across necessary able from anywhere fold immune ongoing total syndrome macroglobulinemia, white data Ib patients chronic patients across white our neutrophil carcinoma, white Phase These time, long-term cells counts clear across renal WHIM and in but mavorixafor in all lymphocyte that of trial. data cells Phase neutropenia. neutropenia as blood a mavorixafor from monocyte mirrored chronic response of in data first and wide trial showed Data to first Waldenström time four increased counts results enrolled to for in periods. two and for blood ongoing an clinical over as healthy were the neutrophil appropriate well from blood presented early spectrum is in Early and the indications our
and low was with to refers in Ib months. state aggregate, in about have the set a severity, our mavorixafor of the of be of risk trial can compelling immunodeficiencies. third people WHIM in how syndrome Enrollment or many primary neutropenia can consistent mild, case could or responses pathway increase recurrent reminder, of continues impact And and XXXX. counts, CXCRX neutropenia the patients It chronic broadly with of wild-type severe of larger that neutrophil infections CXCRX the cellular or disease mutation recurrent encouraged expected of numbers of of second whether and variety a data a via much and quarter irrespective least other in serious by estimated patients. irrespective chronic additional moderate It's mutation Phase with abnormally in XX,XXX in present caused more or us which antagonism think at condition lasting X CXCRX have signaling immunodeficiency, status. sustained three as of and As
We in macroglobulinemia, XXX-milligram clinical mavorixafor, of Phase a treatment inhibitor, people with also results lymphoma Ib ongoing dosing mid-level duration presented rare with trial BTK low the Waldenström median days. and of from B-cell a ibrutinib, with our at XXX-milligram XXX combined
is safety, from and As people mutations XXX% designed needs the serum of in unmet the levels. resulting trial patients. elucidate Phase with Waldenström a mutation MYDXX Sustained evaluable normalization XX and both their a hemoglobin rate of CXCRX of in overall reminder, dose gene. proof demonstrate to decrease significant The and data double mavorixafor levels concept to a and Ib IgM response towards showed trend with
the We A morning patients this or and combination eligible once B XXX dose cohorts in being of All and with also that receive are of XXX-milligram mavorixafor ibrutinib. milligrams announced study. to in now dose cohort daily clear mid-level ongoing was the low- mavorixafor of escalated
mutation. led of of WHIM report our further expect strengthens that we several at and of was data on for second the We also meeting just mutations, available novel these causing more February. than this late At Asthma CXCRX this the half DXXH discovery The U.S. poster alone. Immunology Allergy, presented last X,XXX are AI the website. our the that which More Academy confidence efforts updated research year. to American from announced The in of patients have to ASH mutation there trial our detailed the the in one WHIM is December, of incidence or data during on
recently the continues Immunology in first Conference, Vienna. mutation that working of variation. and the WHIM. Looking will novel in are stemming center forward, variant, another hard who or medical been world-class CIS DXXH conferences from sequenced, our raise into many variants characterized community XXXX, Clinical XXXX WHIM the two with present medical and SXXX At are have our upcoming combined where identified for major educate novel of Society, the participation the published to literature, research the just time at WHIM we awareness This WHIM
combined a preclinical will demonstrating the additive zanubrutinib conference, and be at new month when ibrutinib. including presenting our that any inhibitor, synergistic to AACR I mavorixafor to with commercial little in With near Phase time first the approach our III Next the syndrome. to activity update take of treatment of team today WHIM our data BTK share as clinical would for mavorixafor some insights we like complete, of data
We make resources, patients. along engagement XX. presentation, advocacy Vice to at our Patient disease with The the President we in and to and clinical options entering with worked first us early of disease other available enabled of we development journeys advocacy. who advocacy engaged diverse which our the needs at a III of materials patient process, are center to with disease groups groups, the patient trial clinical patient to unmet experts before mavorixafor decisions our and educate advocacy in the medical patient all treatment long help development. patient or is understand develop appointed on testing Early awareness resources Phase communities through access voices all closely
The access improve diagnosis. support educational genetic second and is our to to testing
Due before the care. you for syndrome As rare WHIM is the awareness, of to current lack syndrome patient visit treatment journeys heterogeneous main with symptom identification long diagnosis often challenges to are diagnosis physician and medical and for and difficult disease. presentation specialties delayed to know, likely often to diagnosed. being WHIM This leads access numerous diagnose. the of symptomatic standard the People
with a an and patient counting to who to like step identification diagnosis. associated indications forward previously, WHIM aid for patients closer we've congenital help to to bring genetic in no-charge sponsored we syndrome carry neutropenia, including As one individuals testing path discussed accurate program and
of artificial ICD-XX thought burden enhance of We inconsistent disease as and an the the as be When symptoms. also is coding the underdiagnosed international for to due use our understanding employ classification or learning tools machine to and to prevalence key intelligence absence of disease. well of code of
identify presentation. artificial due have with phenotypes utilized to that patients undiagnosed look and symptom previously been inconsistent intelligence clinical have learning like WHIM platforms to might We machine
this it's of ongoing research and with a understanding evolve as physician diseases. and with the talked the the often scientists the last as disease that about many case we year, but increasing As communities, is clarity like space there patient WHIM rare our of continues is puzzle to of
creating understand syndrome a about partnerships physician of Collectively, they find medical journeys also increase patients and towards to We strong we a and and to goals. get awareness affairs specialized achieving empowering so available to WHIM their our geared Building treatments. can assembled critical unique feel as answers education have professionals their [indiscernible] team team. a passionately medical that
genetics mentioned, Lastly and underlying as syndrome. we we research conduct continue on to just the
improve programs between genetic undiagnosed our ability continuing to and by icing in-house research advance We research correlations the may variants leverage have benefit can built [ph] new WHIM. that associated event who establish to approval. potentially those bench-to-bedside presentation collaborations identify from to including to strong in mavorixafor We patients, world-class clinical treatment
sustainable not need Of There course, that more we physicians. is on supporting a way. that in and deliver and rare rooted fully patients needed business building our well we is are beyond disease much to
progress made Chief science the adding of We U.S. in XXXX. our to significant Director, with great commercialization slated new including have a are experience. and More Board our life with leadership Commercial Commercial Officer for both company hires, VP key
our of logistic product, U.S. and terms our taken dress to enable work and our in support third-party of the filing appropriate trade ultimate successful support advancing and providers NDA a mavorixafor commercial future terms launch. to are to validation In steps have we commercial batches registration
disease modifying given and U.S. research this syndrome mavorixafor agents WHIM the have rare payers Finally with and education the bearing that European in territories. and on impact population, may importantly, key
quarter open concert in All now patients in deliver working to over it of and for discuss that up call enable our the initiatives to With for the to are to we Adam first for update, platforms the results I ready approval. to our be Adam? event us that questions. of turn these before
